Johnson & Johnson (NYSE:JNJ) announced its quarterly earnings data on Tuesday. The company reported $2.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12, RTT News reports. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter last year, the business earned $2.05 earnings per share. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Johnson & Johnson updated its FY 2019 guidance to $8.62-8.67 EPS and its FY19 guidance to $8.62-8.67 EPS.
Johnson & Johnson stock traded up $2.96 during trading on Wednesday, reaching $135.80. The company had a trading volume of 2,138,727 shares, compared to its average volume of 6,876,548. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The stock’s 50 day moving average price is $130.13 and its two-hundred day moving average price is $134.85. The firm has a market capitalization of $346.60 billion, a price-to-earnings ratio of 16.60, a PEG ratio of 2.22 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33.
Several analysts recently commented on the stock. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Friday, October 11th. Barclays assumed coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price objective for the company. Morgan Stanley reiterated an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $150.91.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.